The End of 280E: How Cannabis Businesses Save Millions Under Schedule III

For as long as legal cannabis has existed in the United States, one section of the Internal Revenue Code has haunted every operator in the industry: Section 280E. Written in 1982 to prevent drug dealers from writing off the costs of their operations, this provision has quietly drained billions of dollars from state-legal cannabis businesses that play by every rule their states impose. With the DOJ's April 23, 2026 rescheduling of medical marijuana to Schedule III, the 280E era is finally beginning to crack — and the financial implications are enormous.

What Section 280E Actually Does

Section 280E is deceptively simple. It states that no deduction or credit shall be allowed for any amount paid or incurred in carrying on a trade or business that consists of trafficking in controlled substances listed in Schedule I or Schedule II.

For any other business in America — a restaurant, a tech startup, a manufacturing plant — standard operating expenses like rent, payroll, marketing, utilities, and insurance are deductible from gross income before calculating tax liability. This is foundational business tax accounting. You earn revenue, subtract your costs, and pay taxes on what's left.

Cannabis businesses under 280E could not do this. They were taxed on gross profit, not net income. The only deduction permitted was the cost of goods sold (COGS) — essentially, the direct cost of producing or purchasing the product itself. Everything else, from the salary of the budtender at the counter to the electricity powering the grow lights, was non-deductible.

The Real-World Impact: 70% Effective Tax Rates

The result was punishing. While a typical American business faces an effective federal tax rate somewhere between 15% and 25%, cannabis operators routinely faced effective rates of 60% to 75% or higher. Some businesses reported paying more in federal taxes than they earned in actual profit.

Consider a hypothetical dispensary generating $2 million in annual revenue with $800,000 in cost of goods sold and $900,000 in operating expenses (rent, payroll, marketing, compliance, etc.). Under normal tax treatment, the business would report $300,000 in taxable income ($2M - $800K - $900K) and owe approximately $63,000 in federal tax at the 21% corporate rate.

Under 280E, that same dispensary could only deduct the $800,000 COGS. Taxable income jumped to $1.2 million, generating a federal tax bill of approximately $252,000 — on a business that actually netted only $300,000. That's an effective rate of 84% on true economic profit.

This isn't a theoretical exercise. These numbers reflect the lived reality of thousands of cannabis businesses that have struggled, and in many cases failed, under 280E's weight.

What Schedule III Changes Immediately

The DOJ's April 23 order moved state-licensed medical cannabis into Schedule III, effective immediately. Because Section 280E only applies to Schedule I and Schedule II substances, qualifying medical cannabis operators can now claim standard business deductions for the first time.

This means medical dispensaries, cultivators, and processors operating under state medical marijuana licenses can immediately begin deducting expenses like employee wages and benefits, rent and facility costs, marketing and advertising (where state law permits), professional services including legal and accounting fees, technology and software, insurance premiums, and compliance costs.

For a typical medical cannabis operation, the shift from 280E taxation to standard tax treatment could reduce the effective federal tax rate by 40 to 60 percentage points. For large multistate operators with significant medical revenue, that translates to millions of dollars in annual savings.

The Catch: Adult-Use Operators Are Still Stuck

The April 23 order is limited in scope. Only medical cannabis operations qualify for immediate Schedule III treatment. Adult-use (recreational) marijuana businesses remain classified under Schedule I, and 280E continues to apply in full.

This creates a bifurcated tax landscape that presents both challenges and opportunities. Multistate operators with both medical and recreational licenses will need to carefully allocate expenses between their qualifying medical operations and their still-280E-burdened recreational operations. This allocation process, known as cost segregation, is complex and will require sophisticated accounting.

For purely recreational operators — a significant portion of the industry in states like Colorado, Oregon, and Washington — the April 23 order provides no immediate tax relief. Their hope rests on the June 29 DEA hearings, which will consider broader rescheduling that would cover all marijuana, including recreational products.

Retroactive Relief: The Potential Windfall

Perhaps the most intriguing element of the DOJ's order is a directive to the Treasury Department to consider retroactive 280E relief for medical cannabis operators. If Treasury acts on this directive, businesses that paid inflated taxes in prior years could file amended returns and reclaim substantial refunds.

The potential magnitude is staggering. The cannabis industry has collectively paid billions in excess taxes under 280E over the past decade. Even partial retroactive relief — covering, say, the last three tax years — could return hundreds of millions of dollars to the industry.

However, retroactive relief is far from guaranteed. Treasury may determine that the legal and logistical complexities of processing thousands of amended returns outweigh the policy benefits. And even if retroactive relief is offered, the IRS backlog for processing amended returns currently stretches well beyond 12 months.

How Businesses Should Prepare

Cannabis tax professionals are advising clients to take several immediate steps. First, operators should segregate their financial records by license type, clearly distinguishing medical revenue and expenses from adult-use operations. This segregation will be essential for claiming deductions and surviving potential IRS scrutiny.

Second, businesses should revisit their accounting methodologies. Many operators have spent years developing creative COGS calculations to maximize the limited deductions available under 280E. Under standard tax treatment, those methodologies may need to be revised or abandoned entirely.

Third, operators should consult with tax professionals about estimated tax payments. With deductions now available, quarterly estimated payments may decrease significantly — providing immediate cash flow relief even before annual returns are filed.

Finally, businesses should begin building documentation packages for potential retroactive claims, gathering historical records, prior returns, and supporting documentation now rather than waiting for Treasury to announce its decision.

The Domino Effect on Capital and Banking

The 280E shift doesn't just save businesses money on taxes. It fundamentally changes the economics that investors, lenders, and financial institutions use to evaluate cannabis companies.

Under 280E, cannabis businesses looked terrible on paper. High effective tax rates compressed margins, reduced free cash flow, and made profitability nearly impossible for many operators. This financial picture deterred mainstream investors and kept banks on the sidelines, fearing that businesses with such razor-thin margins posed unacceptable credit risk.

With standard tax treatment, medical cannabis operators will report dramatically improved financial metrics. Higher net income, better margins, and stronger cash flow will make these businesses more attractive to traditional capital sources. Banks that have been cautiously watching the industry from afar may find that the numbers finally make sense.

What Comes Next

The 280E story isn't over. The June hearings represent the next chapter, and their outcome will determine whether the tax relief stays limited to medical operations or expands to the entire industry. Meanwhile, the SAFER Banking Act's reintroduction in Congress with 14 bipartisan Senate cosponsors represents a parallel effort to solve the financial services problem through legislation rather than rescheduling alone.

For now, medical cannabis operators have reason to celebrate. After more than a decade of paying taxes that no other legal industry would tolerate, the playing field is finally beginning to level.

Related reading: Inside the DOJ's April 23 Schedule III order · Why rescheduling alone won't fix cannabis banking · What happens at the June 29 DEA hearings

Explore cannabis news, find dispensaries, and join the community at Budpedia.